TO CONSULTING AGREEMENT. This Amendment No. 4 to Consulting Agreement (“Amendment No. 4”) is made as of December 18, 2020, by and between Elicio Therapeutics Inc., formerly operating under the name of Vedantra Pharmaceuticals, Inc., with a principal place of business being Oxx Xxxxxxx Xxxxxx, Building 1400 West, Suite 14303, Cambridge, MA 02139 (“Company”) and Dxxxxxxx Advisors, LLC, a Massachusetts limited liability company, with a principal place of business being 90 Xxxxxx Xxxx, Xxxxxxxxxxxx, XX 00000 (“Dxxxxxxx”). Capitalized terms used but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between Dxxxxxxx and the Company dated as of March 13, 2013 (“Agreement”).
TO CONSULTING AGREEMENT. This Amendment No. 1 (“Amendment”), dated as of November 4, 2002 and effective as of January 1, 2002 (the “Effective Date”) is entered into by and between Schrödinger, Inc. (“Schrödinger” or “Company”), a Delaware corporation with an address at 000 Xxxx 00xx Xxxxxx, 00xx Xxxxx, Xxx Xxxx, XX 00000, and Xxxxxxx X. Xxxxxxxx (“Consultant”), an individual with an address at [**].
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“Amendment”) is made as of August 8, 2016 (“Effective Date”), by and between Apellis Pharmaceuticals, Inc. with a principal place of business being 0000 Xxxxxxxx Xxx, Xxxxx X, Xxxxxxxxx, XX 00000 (“Company”) and Xxxxxxxx Advisors, LLC (“Consultant”), with a principal place of business being 00 Xxxxxx Xxxx, Xxxxxxxxxxxx, XX 00000 (“Xxxxxxxx”). Capitalized terms used but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between Xxxxxxxx Advisors and the Company dated as of August 20, 2015 (“Agreement”).
TO CONSULTING AGREEMENT. Dear Rxxxxxx: This is in reference to the Consulting Agreement between VL42, d/b/a Omega Therapeutics, Inc., and Rxxxxxx X. Xxxxx, Ph.D. dated November 7, 2016 (the “Agreement”). All capitalized terms used in this letter and not otherwise defined in this letter shall have the same meaning as in the Agreement.
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“Amendment”) is entered into by and between AlloVir, Inc. (formerly ViraCyte, Inc.), a Delaware corporation (the “Company”), and Xxxx Xxxx (“Consultant”), effective generally as of January 1, 2020 (the “Effective Date”).
TO CONSULTING AGREEMENT. THIS AMENDMENT No. 1 TO CONSULTING AGREEMENT (“Amendment No. 1”) is effective as of March 3, 2023 (hereinafter “Effective Date”) by and between BridgeBio Pharma, Inc. (hereinafter “Company”), a Delaware corporation with offices at 000 Xxxxxxx Xxxxxx, Xxxx Xxxx, Xxxxxxxxxx 00000, and Xxxxx XxXxxxxxx (hereinafter “Consultant”), located at [***] (each herein referred to as a “Party” and collectively as “Parties”).
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“Amendment”) is made and entered into as of January 10, 2017 (“Amendment Effective Date”) by and between ACUCELA INC., a Washington corporation (“Company”) and Xxxxxx Xxxxxxxx (“Consultant”).
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“Amendment No. 1”) is made as of May 16, 2023, by and between Bionomics Limited, an Australian corporation, with its principal place of business being 00 Xxxxxxxxx Xxxxxx, Thebarton SA 5031, Australia (“Company”) and Xxxxxxxx Advisors, LLC, a Massachusetts limited liability company, with a principal place of business being 00 Xxxxxx Xxxx, Xxxxxxxxxxxx, XX 00000, XXX (“Xxxxxxxx”). Capitalized terms used but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between Xxxxxxxx and the Company dated as of July 16, 2023, as may be amended from time to time (“Agreement”).
TO CONSULTING AGREEMENT. Please acknowledge your acceptance of the foregoing Amendment by signing and returning a copy to the undersigned whereupon it shall become a binding agreement between us.
TO CONSULTING AGREEMENT. THIS ADDENDUM NO. 1 TO AGREEMENT, dated as of July 8, 2020, is entered into by GNC Holdings, Inc. (“Merchant”) and a joint venture comprised of Tiger Capital Group, LLC (“Tiger”) and Great American Group, LLC (“GA”) (Tiger together with GA, “Consultant”).
